ArticlePloS one2013
Spinal actions of lipoxin A4 and 17(R)-resolvin D1 attenuate inflammation-induced mechanical hypersensitivity and spinal TNF release.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Lipoxin A4 and Resolvin D1 Preserve Neural Inductive Capacity of Dental Pulp Stem Cells Cultured Under Inflammatory Conditions.Cell biology international · 2026Article
- The mechanisms of specialized pro-resolving mediators in pain relief: neuro-immune and neuroglial regulations.Frontiers in immunology · 2025Review
- 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway.Drug design, development and therapy · 2025Article
- Systemic administration of Resolvin D1 reduces cancer-induced bone pain in mice: Lack of sex dependency in pain development and analgesia.Cancer medicine · 2024Article
- Therapeutic activity of lipoxin AFrontiers in immunology · 2023Article
- Roles of Resolvins in Chronic Inflammatory Response.International journal of molecular sciences · 2022Review
- Specialized pro-resolution mediators in the bladder: Receptor expression and recovery of bladder function from cystitis.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- TNF-α induces AQP4 overexpression in astrocytes through the NF-κB pathway causing cellular edema and apoptosis.Bioscience reports · 2022Article
- Lipoxins in the Nervous System: Brighter Prospects for Neuroprotection.Frontiers in pharmacology · 2022Review
- Specialized proresolution mediators in the bladder: annexin-A1 normalizes inflammation and bladder dysfunction during bladder outlet obstruction.American journal of physiology. Renal physiology · 2021Article
- Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?International journal of molecular sciences · 2021Review
- Fish Hydrolysate Supplementation Containing n-3 Long Chain Polyunsaturated Fatty Acids and Peptides Prevents LPS-Induced Neuroinflammation.Nutrients · 2021Article
- Role of Specialized Pro-Resolving Mediators in Neuropathic Pain.Frontiers in pharmacology · 2021Review
- Spinal neuronal excitability and neuroinflammation in a model of chemotherapeutic neuropathic pain: targeting the resolution pathways.Journal of neuroinflammation · 2020Article
- Functions of resolvin D1-ALX/FPR2 receptor interaction in the hemoglobin-induced microglial inflammatory response and neuronal injury.Journal of neuroinflammation · 2020Article
- Alzheimer's Disease and Specialized Pro-Resolving Lipid Mediators: Do MaR1, RvD1, and NPD1 Show Promise for Prevention and Treatment?International journal of molecular sciences · 2020Review
- n-3 Polyunsaturated Fatty Acids and Their Derivates Reduce Neuroinflammation during Aging.Nutrients · 2020Review
- Astrocytes in chronic pain and itch.Nature reviews. Neuroscience · 2019Review
- N-3 Polyunsaturated Fatty Acids and the Resolution of Neuroinflammation.Frontiers in pharmacology · 2019Review
- Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoxins and resolvins have anti-inflammatory and pro-resolving actions and accumulating evidence indicates that these lipid mediators also attenuate pain-like behavior in a number of experimental models of inflammation and tissue injury-induced pain. The present study was undertaken to assess if spinal administration of lipoxin A4 (LXA4) or 17 (R)-resolvin D1 (17(R)-RvD1) attenuates mechanical hypersensitivity in the carrageenan model of peripheral inflammation in the rat. Given the emerging role of spinal cytokines in the generation and maintenance of inflammatory pain we measured cytokine levels in the cerebrospinal fluid (CSF) after LXA4 or 17(R)-RvD1 administration, and the ability of these lipid metabolites to prevent stimuli-induced release of cytokines from cultured primary spinal astrocytes. We found that intrathecal bolus injection of LXA4 and17(R)-RvD1 attenuated inflammation-induced mechanical hypersensitivity without reducing the local inflammation. Furthermore, both LXA4 and 17(R)-RvD1 reduced carrageenan-induced tumor necrosis factor (TNF) release in the CSF, while only 17(R)-RvD1attenuated LPS and IFN-γ-induced TNF release in astrocyte cell culture. In conclusion, this study demonstrates that lipoxins and resolvins potently suppress inflammation-induced mechanical hypersensitivity, possibly by attenuating cytokine release from spinal astrocytes. The inhibitory effect of lipoxins and resolvins on spinal nociceptive processing puts them in an intriguing position in the search for novel pain therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.